This site is intended for healthcare professionals
Drug information


Read time: 44 mins
Last updated: 06 May 2020
Published: 06 Jul 2021

4.1 Therapeutic indications


Adults and adolescents aged 13 years and above

- Adjunctive or monotherapy treatment of partial seizures and generalised seizures, including tonic clonic seizures.

- Seizures associated with Lennox Gastaut syndrome. Lamotrigine dispersible tablets are given as adjunctive therapy but may be the initial antiepileptic drug (AED) to start with in Lennox Gastaut syndrome.

Paediatric population aged 2 to 12 years

- Adjunctive treatment of partial seizures and generalised seizures, including tonic clonic seizures and the seizures associated with Lennox Gastaut syndrome.

- Monotherapy of typical absence seizures.

Bipolar disorder

Adults aged 18 years and above

- Prevention of depressive episodes in patients with bipolar I disorder who experience predominantly depressive episodes (see section 5.1).

Lamotrigine dispersible tablets are not indicated for the acute treatment of manic or depressive episodes.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).